NCT06524544 2026-03-18
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
University of Iowa
Bristol-Myers Squibb
ImmunityBio, Inc.